{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T23:05:17Z","timestamp":1769555117652,"version":"3.49.0"},"reference-count":38,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Reports"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Dasatinib, a potent second\u2010generation tyrosine kinase inhibitor (TKI), is highly effective in chronic myeloid leukemia in chronic phase (CML\u2010CP) resistant to imatinib at standard dosing (100\u2009mg daily), but is often limited by adverse events. Emerging evidence suggests low\u2010dose dasatinib (50\u2009mg daily) may maintain efficacy with improved safety, but data in imatinib\u2010resistant CML\u2010CP remain limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of low\u2010dose dasatinib (50 mg daily) in patients with imatinib\u2010resistant CML\u2010CP and to identify predictors of treatment response and disease progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and Results<\/jats:title>\n                    <jats:p>\n                      This retrospective cohort study included 53 adults with imatinib\u2010resistant CML\u2010CP treated with low\u2010dose dasatinib at a tertiary center in Northern India (2002\u20132025). Early molecular response (EMR), major molecular response (MMR), deep molecular response (DMR), progression\u2010free survival (PFS), overall survival (OS), and adverse events were assessed. Multivariate Cox regression identified predictors of poor response and disease progression. Among 53 patients (median age 50\u2009years), 41.5% achieved MR4.5, 20.8% MR4.0, and 15.1% MMR without DMR. Prior loss of MMR on imatinib significantly correlated with a superior response to dasatinib (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002). TKD mutations were present in 32.1%; the T315I mutation, high ELTS risk, and baseline BCR\u2010ABL1\u2009\u27e9\u2009100% independently predicted poor response. Clinically significant adverse events occurred in 49.1%, primarily cytopenias and pleural effusion. Among our cohort, 22.6% required a TKI switch due to inadequate response and 7.5% due to intolerance.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Low\u2010dose dasatinib is effective and tolerable in imatinib\u2010resistant CML\u2010CP, with nearly two\u2010thirds achieving DMRs. Predictive biomarkers (T315I mutation, high ELTS risk, high baseline BCR\u2010ABL1) can guide dose optimization.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cnr2.70400","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T12:08:25Z","timestamp":1767960505000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real\u2010World Outcomes With Low\u2010Dose Dasatinib (50\u2009mg) in Imatinib\u2010Resistant Chronic Myeloid Leukemia in Chronic Phase: A Retrospective Analysis of Efficacy and Safety"],"prefix":"10.1002","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2011-4760","authenticated-orcid":false,"given":"Nandhini","family":"Gangadaran","sequence":"first","affiliation":[{"name":"Department of Hematology Sanjay Gandhi Post Graduate Institute of Medical Sciences  Lucknow Uttar Pradesh India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5007-8602","authenticated-orcid":false,"given":"Harshal","family":"Mamlekar","sequence":"additional","affiliation":[{"name":"Department of Hematology Sanjay Gandhi Post Graduate Institute of Medical Sciences  Lucknow Uttar Pradesh India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7971-9776","authenticated-orcid":false,"given":"Souvik","family":"Saha","sequence":"additional","affiliation":[{"name":"Department of Hematology Sanjay Gandhi Post Graduate Institute of Medical Sciences  Lucknow Uttar Pradesh India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6645-8052","authenticated-orcid":false,"given":"Rajesh","family":"Kashyap","sequence":"additional","affiliation":[{"name":"Department of Hematology Sanjay Gandhi Post Graduate Institute of Medical Sciences  Lucknow Uttar Pradesh India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1125-3428","authenticated-orcid":false,"given":"Sanjeev","family":"Yadav","sequence":"additional","affiliation":[{"name":"Department of Hematology Sanjay Gandhi Post Graduate Institute of Medical Sciences  Lucknow Uttar Pradesh India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8285-2092","authenticated-orcid":false,"given":"Khaliqur","family":"Rahman","sequence":"additional","affiliation":[{"name":"Department of Hematology Sanjay Gandhi Post Graduate Institute of Medical Sciences  Lucknow Uttar Pradesh India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3427-9188","authenticated-orcid":false,"given":"Ruchi","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Hematology Sanjay Gandhi Post Graduate Institute of Medical Sciences  Lucknow Uttar Pradesh India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0875-6032","authenticated-orcid":false,"given":"Mona","family":"Vijayaran","sequence":"additional","affiliation":[{"name":"Department of Hematology Sanjay Gandhi Post Graduate Institute of Medical Sciences  Lucknow Uttar Pradesh India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7558-2656","authenticated-orcid":false,"given":"Manish","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Hematology Sanjay Gandhi Post Graduate Institute of Medical Sciences  Lucknow Uttar Pradesh India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6069-8768","authenticated-orcid":false,"given":"Dinesh","family":"Chandra","sequence":"additional","affiliation":[{"name":"Department of Hematology Sanjay Gandhi Post Graduate Institute of Medical Sciences  Lucknow Uttar Pradesh India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27443"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-193269"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022457"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)03030-X"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2009.1.461"},{"key":"e_1_2_10_7_1","first-page":"205","article-title":"Dasatinib in the Treatment of Imatinib Refractory Chronic Myeloid Leukemia","volume":"3","author":"Ramchandren R.","year":"2009","journal-title":"Biologics"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V112.11.3225.3225"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24423"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24734"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2023.05.009"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26689"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-02048-y"},{"key":"e_1_2_10_14_1","first-page":"225","article-title":"Guide to Interpreting Disease Responses in Chronic Myeloid Leukemia","volume":"3","author":"Galinsky I.","year":"2012","journal-title":"Journal of the Advanced Practitioner in Oncology"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-154344"},{"key":"e_1_2_10_16_1","article-title":"Outcomes of Dose Escalation of Imatinib in Chronic Myeloid Leukemia Patients: A Retrospective Analysis From an Indian University Teaching Hospital","volume":"16","author":"Yadav R.","year":"2024","journal-title":"Cureus"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1369246"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32504"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-511592"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3516"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.8899"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0805-1"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024012655"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00823-9"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V116.21.1240.1240"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2010-0055"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404236"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012082"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-326405"},{"key":"e_1_2_10_30_1","first-page":"93","article-title":"Detection of BCR\u2010ABL Mutations and Resistance to Imatinib Mesylate","volume":"125","author":"Branford S.","year":"2006","journal-title":"Methods in Molecular Medicine"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.6.2056"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-02-335497"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-326843"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/leusup.2014.1"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30066-2"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24432"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-05760-6"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1113462"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-020-01584-6"}],"container-title":["Cancer Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cnr2.70400","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cnr2.70400","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cnr2.70400","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T10:11:59Z","timestamp":1769508719000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cnr2.70400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1002\/cnr2.70400"],"URL":"https:\/\/doi.org\/10.1002\/cnr2.70400","archive":["Portico"],"relation":{},"ISSN":["2573-8348","2573-8348"],"issn-type":[{"value":"2573-8348","type":"print"},{"value":"2573-8348","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"2025-05-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70400"}}